- Home
- REXR vs LEGN Comparison
REXR vs LEGN Comparison
Compare REXR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REXR | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | REXR | LEGN |
|---|---|---|
| Price | $34.74 | $19.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $41.60 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.28 | $46.27 |
| Revenue Next Year | $3.44 | $28.77 |
| P/E Ratio | $43.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.68 | $16.24 |
| 52 Week High | $44.38 | $45.30 |
Technical Indicators
Market Signals| Indicator | REXR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.99 | 51.45 |
| Support Level | $33.82 | $17.46 |
| Resistance Level | $37.56 | $23.68 |
| Average True Range (ATR) | 0.75 | 0.95 |
| MACD | -0.18 | 0.22 |
| Stochastic Oscillator | 2.80 | 41.87 |
Price Performance
Historical ComparisonAbout REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.